#San Jose #Costa Rica #SteinCares #Biosimilars #Shilpa Biologicals

SteinCares and Shilpa Biologicals Join Forces to Enhance Biosimilar Accessibility

In a significant move for the healthcare landscape in Latin America, SteinCares, a premier specialty healthcare organization, has entered into a strategic licensing agreement with Shilpa Biologicals Pvt. Ltd. (SBPL), a fully integrated biopharmaceutical company. This partnership is poised to revolutionize the accessibility of biosimilars in the region and marks Shilpa Biologicals' first foray into the Latin American market.

Details of the Agreement

The collaboration grants SteinCares exclusive rights to register, commercialize, and distribute a biosimilar throughout Latin America. Meanwhile, SBPL will manage the product development and commercial manufacturing, leveraging its expertise from its facility in Dharwad, India. This union combines SBPL's robust capabilities in biologics development with SteinCares' integrated regional platform, creating a formidable force in the biosimilars sector.

Mitchell Waserstein, CEO of SteinCares, expressed enthusiasm about the partnership, emphasizing that it reinforces their standing as a leader in biosimilars. He stated, "By partnering with Shilpa Biologicals, we are set to enhance patient access to innovative and cost-effective treatments. This agreement not only solidifies our position in the biosimilars market but also illustrates our commitment to serving global biopharmaceutical companies navigating the complexities of Latin America's healthcare environment."

The Vision for Patient Access

The goal of this partnership is clear: to improve access to affordable treatments for patients across Latin America. Dr. Sridevi Khambhampaty, CEO of Shilpa Biologicals, highlighted the trust in SteinCares as a reliable partner, noting their proven track record in the registration and commercialization of specialized therapies across the region. Through this collaboration, Dr. Khambhampaty aims to make safe treatments more widely available, ultimately benefiting patients and healthcare systems alike.

SteinCares’ Impact in Latin America

With over 45 years of experience, SteinCares has been pivotal in increasing the availability of innovative treatments in over 30 Latin American countries. By creating a one-stop-shop platform, SteinCares not only focuses on pioneering biosimilar therapies but also emphasizes comprehensive healthcare solutions tailored for the region's diverse needs.

Shilpa Biologicals: A Commitment to Quality

Shilpa Biologicals, a subsidiary of Shilpa Medicare Limited, operates under a hybrid Contract Development and Manufacturing Organization (CDMO) model. It specializes in providing development, manufacturing, and ready-to-license formulations in critical areas such as immunology, oncology, and ophthalmics. This solid foundation positions Shilpa Biologicals to bring high-quality biosimilars to the Latin American market effectively.

Future Prospects

The licensing agreement is just the beginning of what the two companies hope will be a long-term partnership. As they work together to expand Shilpa's biosimilars portfolio in Latin America, this collaboration is expected to yield significant value for patients in the region while providing a strong foundation for future collaborations across key international markets.

This strategic move by SteinCares and Shilpa Biologicals signifies a crucial step toward addressing the accessibility challenges faced by patients in Latin America, laying the groundwork for a more inclusive healthcare system that prioritizes affordable and effective treatment options.